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prosthetic graft endothelialization through an
isolation loop-graft model
Timothy Pennel, MBChB, Peter Zilla, MD, PhD, and Deon Bezuidenhout, PhD, Cape Town, South Africa
Background: In humans, transanastomotic endothelial outgrowth onto the surface of prosthetic vascular grafts is limited
to the immediate perianastomotic region, even after years of implantation. In contrast, continual transanastomotic
outgrowth together with short graft lengths has led to early endothelial conﬂuence in most animal models pre-empting
endothelialization through transmural capillary sprouting. We describe an isolation loop-graft model that clearly sepa-
rates these distinctly different events.
Methods: Baseline transanastomotic endothelialization was assessed by implanting low-porosity expanded polytetra-
ﬂuoroethylene grafts (ePTFE; internal diameter 1.7 mm; internodal distance 15-25 mm; 14.26 1.6 mm long) for 2, 4, and
6 weeks (n[ 6/time point) in the abdominal aorta of Wistar rats. High-porosity polyurethane (internal diameter 1.7 mm-
150 mm pore size) grafts were then interposed (“welded”) into the midsection of the ePTFE grafts for 2, 4, 6, and 8 weeks
(n[ 6/time point). Looping the interposition grafts increased their length to 70.36 8.3 mm. After implantation periods
of 6, 8, 12, and 24weeks (n[ 8/time point) isolation loop grafts were analyzed by light, immune-ﬂuorescence (CD31) and
scanning electron microscopy, and endothelialization was expressed as maximal transanastomotic endothelial outgrowth
(Imax), mean transanastomotic outgrowth (Imean), and segmental graft coverage (GSE).
Results: Transanastomotic outgrowth slowed down between 2 and 6 weeks of implantation (proximal: [Imax from
0.9 6 0.5 to 0.3 6 0.3 mm/wk; P < .04; Imean from 0.3 6 0.1 to 0.2 6 0.1 mm/wk; nonsigniﬁcant (NS)]; distal: [Imax
from 0.7 6 0.3 to 0.3 6 0.2 mm/wk; P < .02; Imean from 0.3 6 0.2 to 0.2 6 0.0 mm/wk; NS]) but remained constant
thereafter (Imax [ 0.5 6 0.2 mm/wk; Imean [ 0.4 6 0.2 mm/wk at 24 weeks NS). In straight composite grafts, the
ePTFE separation zones were too short to isolate transmural ingrowth beyond week 4. In contrast, a broad endothelial-
free separation zone was preserved in all looped composite grafts even after half a year of implantation (25.9 6 5.9 vs
8.7 6 4.9 mm proximally and 21.9 6 13.4 vs 12.3 6 6.2 mm distally at 6 and 24 weeks, respectively). Ninety-three
percent of patent loop-grafts showed isolated transmural midgraft endothelium after 4 weeks and 97% after 6 weeks.
Midgraft preconﬂuence was reached by 6 weeks (GSE [ 55 6 45%) and conﬂuence between week 12 and 24 (GSE [
95.0 6 10.0% and 84.0 6 30.13%). The subintimal thickness stayed constant with a nonsigniﬁcant trend toward
regression (91.8 6 93.9 mm vs 71.4 6 59.4 mm at 6 and 24 weeks, respectively; NS).
Conclusions: Transmural endothelialization can be clearly distinguished from transanastomotic outgrowth in a high
throughput rat model. A looped interposition graft model provides sufﬁcient isolation length to separate the two events
for up to half a year and does not result in an increase in intimal hyperplasia. (J Vasc Surg 2013;58:1053-61.)
Clinical Relevance: Although the mode of graft deployment has changed over the years, the problem of an absent surface
endothelium remains, whether small- to medium-diameter grafts are surgically implanted or placed endovascularly as
“covered stents.” In contrast to humans, most animal models experience progressive transanastomotic endothelial
outgrowth. Together with graft lengths that were too short, the clinically irrelevant transanastomotic endothelialization
inadvertently led to early endothelial conﬂuence in the vast majority of experimental vascular graft studies pre-empting or
concealing alternative modes of endothelialization. The isolation loop-graft model we propose allows the long-term
differentiation of the different modes of endothelialization in a small animal screening model.the Christian Barnard Department of Cardiothoracic Surgery, Cardio-
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://dx.doi.org/10.1016/j.jvs.2012.11.093Synthetic small- to medium-sized vascular grafts have
inherent shortcomings regardless of whether they are
surgically implanted or endovascularly placed as “covered
stents.” One such shortcoming is the lack of an endothelial
lining even after years of clinical implantation. This absence
of a physiological intima is a main reason for lower patency
rates compared with arterial or vein grafts.1
Although sophisticated surface coatings with carbon2;
heparin3,4; polypropylene-sulﬁde-polyethylene glycol5;
thrombomodulin4; acrylate-phospholipid6 or elastin poly-
mers,7 or the release of thromboinhibitory molecules
such as nitric oxide8 have been partially successful in
improving graft performance, a functional endothelium
remains the most desirable nonthrombogenic surface.1,91053
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lining on synthetic grafts would be transanastomotic
outgrowth from adjacent arteries. However, for reasons
incompletely understood, transanastomotic endothelializa-
tion in humans does not reach further than the immediate
perianastomotic region even after decades of implanta-
tion.10 Together with graft lengths of up to 50 to 60 cm,
it is evident that endothelialization strategies that hinge on
transanastomotic outgrowth are futile in man. Yet, 40 years
of vascular graft research have counterintuitively and often
unintentionally focused on transanastomotic endothelializa-
tion.1 By choosing short graft lengths in animal models that
lack the transanastomotic outgrowth stoppage of humans,
most experimental prostheses were transanastomotically
fully endothelialized at the time of explantation making it
impossible to assess any other mode of endothelialization.
In over 90% of large animal studies performed over almost
4 decades, the average graft length was 5.5 cm in Dacron
and expanded polytetraﬂuoroethylene (ePTFE) grafts and
even shorter in polyurethane (PU) grafts.1 Although slightly
longer grafts have been implanted in more recent years
(two-thirds are still shorter than 7 cm), the endothelializa-
tion observed was still largely due to the vigorous transanas-
tomotic outgrowth intrinsic to the animal models used. The
same outgrowth distance, for instance, which takes 56
weeks in humans to be covered is reached after 3.5 weeks
in dogs.1 Furthermore, apart from the differences between
species, senescence also needs to be considered. As an
example, senescent baboons come closest to the situation
in man, yet the transanastomotic endothelialization in sen-
escent dogs is comparable to that in juvenile baboons.1 To
further complicate the issue, anatomic dimensions of species
play a role, as it is impossible to directly compare outgrowth
distances in rats with those in large animals.1 Yet, if
expressed in relative terms, juvenile large and small animals
have comparable transanastomotic outgrowth rates. Both
rats and sheep, for instance, cover a distance equivalent to
the inner diameter of the infrarenal aorta within a month.1
Given the fact that transanastomotic endothelialization
is not only irrelevant in humans but also highly variable in
animals, experimental models that are capable of investi-
gating alternative modes of endothelialization without
transanastomotic interference are critically needed. The
three alternative modes of endothelialization that such
models theoretically need to allow to study in isolation are
transmural capillary sprouting, fallout healing from the
blood stream, and the transplantation of autologous endo-
thelial cells onto or into the scaffold of a synthetic graft.
The latter approach represented the ﬁrst broad manifes-
tation of tissue engineering in the late 1970s and 1980s.
Although its single-stage variant resulted in too low an inoc-
ulum under clinical conditions,11,12 the two-stage approach
utilizing cell culture techniques13,14 served as a proof of
superiority of endothelialized synthetic vascular grafts.15,16
However, inasmuch as tissue engineering approaches such
as in vitro endothelialization were able to close the gap
between prosthetic and autologous grafts,15,16 their
demand for a high level of methodological sophisticationmakes them an unrealistic solution for the many thousands
of synthetic vascular grafts annually implanted in patients.
To investigate whether transmural ingrowth or fallout
healing could hold a realistic key to spontaneous in vivo
endothelialization, animal models are critically required to
clearly separate these events from transanastomotic
outgrowth. A similar need exists to separate transanasto-
motic intimal hyperplasia (often referred to as pannus
outgrowth) from independently developing subendothelial
tissue. While transanastomotic intimal hyperplasia is a major
contributor to prosthetic graft failure, subintimal tissue in
the midgraft region may either be ﬂow-controlled and as
such, self-limiting or lumen encroaching like its anasto-
motic counterpart.
We have previously proposed a model that isolates
a high-porosity midsegment from transanastomotic
outgrowth through sufﬁciently long proximal and distal
low-porosity segments.1 In the present study, we realized
this concept in a high-throughput small animalmodel allow-
ing adequate isolation lengths through looping of the graft.
METHODS
Study design. An infrarenal aortic interposition model
was chosen in maleWistar rats (4496 50 g). Fourteenmilli-
meter long (14.2 6 1.6 mm) straight low-porosity ePTFE
grafts (n ¼ 18/6 per group) were implanted and explanted
over increasing time intervals (2; 4; 6 weeks) to assess
transanastomotic endothelialization. Subsequently, straight
ePTFE grafts of equal length had 4-mm-long high-porosity
PU segments centrally inserted (total length, 18.4 6
1.5 mm) to determine the time point from which onward
transmural and transanastomotic endothelialization become
indistinguishable (n¼ 24/6 per group; implantation period
2, 4, 6, and 8 weeks). Finally, loop grafts (implantation
length 70.3 6 8.3 mm; n ¼ 32/8 per group) with a high-
porosity PU segment in the midsection were implanted
allowing a manifold length extension of the isolating low-
porosity ePTFE segments and thereby ensuring clearly
discernible endothelial free zones over implantation periods
of up to half a year (6, 8, 12, and 24 weeks) (Fig 1). To
exclude the possibility of transmural endothelialization
occurring through gaps at the interface between midgraft
and the ePTFE isolation segments, control composite grafts
were implanted where the interposition segment also con-
sisted of low-porosity ePTFE.
Vascular grafts. Low-porosity ePTFE grafts (Zeus
Industrial Products Inc, Orangeburg, SC) (internal diam-
eter [ID]:1.77 6 0.05 mm; outer diameter [OD]:2.48 6
0.05 mm; internodal distance [IND]:15-25 mm) without
external wrap were used throughout. The high-porosity PU
(Medtronic Inc, Minneapolis, Minn) midgraft segments
were manufactured as previously described1,17,18 using
spherical gelatin beads (Thies Technologies, St. Louis, Mo)
to create well-deﬁned interconnected ingrowth spaces (pore
size, 156 6 2 mm with 76 6 2 mm interconnections).
Midgraft segments were “welded” to the two ePTFE
segments with 10% PU chloroform. The looped grafts
(manufacturing length, 90 mm; loop diameter, 15 mm; PU
Fig 1. Straight and loop grafts are interpositioned between the
renal arteries and the aortic bifurcation of Wistar rats. An 8-mm-
long high-porosity (pore size, 156 mm; minimal interconnecting
pore size, 76 mm) polyurethane graft segment (gray) is “welded”
into the midpart of a low-porosity expanded polytetraﬂuoro-
ethylene (ePTFE) graft (internodal distance [IND] 15-25 mm)
(white). As the midgraft segment is ingrowth permissible for trans-
mural capillaries and arterioles, whereas the “isolation arms” on
each side are impenetrable for blood vessels, transmural endotheli-
alization can be investigated without interference by trans-
anastomotic endothelialization. Looping the graft increased the
isolation length, ensuring an endothelial-free zone.
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 4 Pennel et al 1055interposition segment, 8 mm) were identically manufac-
tured but heat-set in 75C water for 3 minutes over a spi-
raled 1.5-mm nylon cord that preserved the loop shape
without kinking. Every 10th graft was excluded from
implantation for quality control analyses.
Surgery. All animal experiments were approved by the
Animal Research and Ethics Committee of the University of
Cape Town and were in compliance with the Guide for the
Care and Use of Laboratory Animals, Institute of Labora-
tory Animal Resources, Commission on Life Sciences,
National Research Council. Operations were performed
under general anesthesia (isoﬂurane 1.75% nosecone) and
under sterile conditions in spontaneously breathing animals.
After a midline laparotomy, the high-porosity PU segment
was pre-clotted with venous blood following which the
infrarenal aorta was mobilized and heparin was administered
(1 mg/kg) prior to aortic cross-clamping. The abdominal
aorta was transected in a beveled manner and grafts were
anastomosed with interrupted 9-0 nylon (Ethilon; Johnson
& Johnson, New Brunswick, NJ) using an operation
microscope (Zeiss Universal S3, Oberkochen, Germany).
The cross-clamp time did not differ between the straight(44.1 6 10.6 minutes) and looped groups (42.7 6
8.3 minutes; nonsigniﬁcant [NS]). If grafts continued to
ooze following clamp removal, the aorta was clamped and
unclamped for 1 minute in an intermittent fashion until the
hemostasis was achieved. The looped grafts were secured to
the lumbar muscles to prevent twisting. All grafts were
covered by the retroperitoneum. Prior to closure, bupre-
norphine (0.1 mg/kg) was administered subcutaneously.
Animals were kept in temperature-controlled rooms with
a 12-hour light/dark cycle and fed ad libitum. Initially, they
were kept in separate cages during their ﬁrst 3 days post-
operatively receiving twice-daily subcutaneous analgesia
(buprenorphine 0.1 mg/kg), following which they
were paired for social interaction. At the end of the
implantation period, rats were euthanized under isoﬂurane
anesthesia and retroperitoneal tissue incorporation was
conﬁrmed (Fig 2). After the distal aorta had been inspected
for patency, 1 mg/kg heparin was administered via the
inferior vena cava prior to the animal being sacriﬁced
by exsanguination. On apnea, the chest was opened and
a 22-gauge cannula was transapically advanced into the
ascending aorta. Phosphate-buffered solution (37C) was
perfused ﬁrst until clear ﬂuid drained out the transected
right atrium (minimum of 200 mL) followed by 150 mL
of 1% paraformaldehyde perfusion-ﬁxation. Vascular graft
angiography (Philips BV Pulsera; Philips, Amsterdam,
The Netherlands) was performed with 10 mL nonionic
contrast medium (Omnipaque 300; GE Healthcare, Little
Chalfont, United Kingdom) (Fig 3). The graft was then
explanted en bloc.
Histologic and scanning electron microscopy
(SEM) analyses of endothelialization and tissue incor-
poration. Following macrophotography and excision of
2-mm-long midgraft cross-sections, all grafts were divided
longitudinally for histologic and SEM analysis except for
two loop grafts per group that were exclusively used for
histologic serial sections. SEM specimens were postﬁxed in
glutaraldehyde (2.5%; 0.1 M/L phosphate buffer; 24
hours; 4C), dehydrated in graded ethanol, critical point
dried (Polaron, Evanstone, Ill), sputter coated, and
analyzed in a Jeol JSM 5200 using Image J v1.41 (National
Institute of Health, Bethesda, Md) image analysis software.
Maximal transanastomotic endothelial outgrowth distance
(Imax) was perpendicularly measured from the anastomoses
to the tip of the furthest reaching endothelial “tongue”
(Fig 4). The mean transanastomotic outgrowth (Imean)
deﬁned as the area of the endothelialized region divided by
the average width (w) of the sample, can be written in
terms of the areas A1, A2 and Imax as shown below:
ðA1 þ A2Þ ¼ Imax  w
A1 ¼ Imean  w
Imean ¼

A1
A1 þ A2

 Imax
Overall graft endothelialization (GE) was expressed as
percentage of endothelial covered surface of an entire graft,
whereas (GSE) refers to endothelialization of a graft
Fig 3. Angiogram depicting the loop graft in situ taken immedi-
ately after euthanasia. After 24 weeks of implantation, the looped
graft appears undistorted and without any kinks. No signs of
midgraft narrowing suggest lumen-encroaching subintimal tissue
formation.
Fig 2. Isolation loop graft at explantation. While one can still
recognize the high-porosity midgraft segment after 12 weeks of
implantation (arrow), the entire loop has been well incorporated
into retroperitoneal tissue.
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deﬁned as the minimum distance between the furthest
reaching points of opposing transanastomotic endothelial
outgrowth. Samples for histology were postﬁxed in zinc
solution (24 hours; 4C), embedded in parafﬁn, and
stained with hematoxylin (Merck, Damstadt, Germany)
and eosin (BDH; WWR International, Poole, England)
(H&E), Miller and Masson elastin trichrom stain, anti-
CD31 (Fitzgerald International, North Acton, Mass),
anti-factor VIII von Willebrand (Dako, AS, Glostrup,
Denmark) antibodies for immune histochemistry to label
endothelial cells, and anti-alpha actin (Abcam, Cambridge,
UK) antibodies to label smooth muscle cells. Slides were
viewed under a Nikon eclipse 90i microscope (Nikon,
Tokyo, Japan). The histologic presence of surface endothe-
lium was cross-referenced against the SEM analysis to
conﬁrm interpretation. Neo-intimal hyperplasia was
deﬁned as the tissue layer between the graft and the blood
surface excluding thrombus appositions.
Statistical analysis. Statistical tests were performed
with STATA (StataCorp 2011, Stata Statistical Software:
Release 12; StataCorp LP, College Station, Tex) Results
were expressed as mean 6 SD for continuous variables.
The unpaired t-test was used to compare normally distrib-
uted data and Mann-Whitney for nonparametric values.
The level of signiﬁcance was set at P < .05.
RESULTS
Overall graft patencies were 100% (18/18) for straight
ePTFE grafts, 100% for straight ePTFE/ePTFE composite-graft controls, 92% for straight ePTFE/PU composite grafts
(22/24), and 84% (27/32) for looped ePTFE/PU
composite grafts (mean implantation time 28 6 11.7 days;
28 6 0 days; 35 6 15.9 days; and 87.5 6 49.7 days,
respectively).
From week 2, all grafts showed zones of smooth, glis-
tening blood surfaces stretching across both aortic anasto-
moses and expanding with increasing implantation time.
From week 4 onward, similar tissue began to emerge on
the midgraft PU sections.
Transanastomotic endothelial outgrowth
ePTFE grafts (straight). After 6 weeks, there was no
signiﬁcant difference between proximal and distal
outgrowth (Imax ¼ 2.9 6 1.4 vs 2.1 6 0.6 mm; NS/Imean
¼ 0.9 6 0.8 vs 1.1 6 0.3; NS). Indexed over time, trans-
anastomotic outgrowth slowed down between 2 and 6
weeks of implantation (proximal: Imax from 0.9 6 0.5 to
0.3 6 0.3 mm/wk; P < .04/Imean ¼ 0.3 6 0.1 vs 0.2 6
Fig 5. Compilation of individual straight (rectangles) and looped
(circles) composite grafts in relation to the isolation of midgraft
endothelium. Green indicates those grafts where clear endothelial-
free zones were present between midgraft and transanastomotic
endothelium, whereas red indicated a coalescence of the two across
the entire graft length. It is obvious that from week 2 onward,
isolation begins to disappear in the shorter straight grafts (no ﬁlling,
absentmidgraft endothelium;X, loop graft remained nonembedded;
black, occluded graft).
Fig 4. Maximal transanastomotic endothelial outgrowth distance
(Imax) was perpendicularly measured from the anastomoses to the
tip of the furthest-reaching endothelial “tongue.” The mean
transanastomotic ingrowth (Imean) deﬁned as the area of the
endothelialized region divided by the average width (w) of the
sample, can be written in terms of the areas A1, A2, and Imax as
follows:
ðA1 þ A2Þ ¼ Imax  w
A1 ¼ Imean  w
Imean ¼

A1
A1 þ A2

 Imax
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week; P < .02/Imean¼ 0.3 6 0.2 vs 0.2 6 0.0; NS). Total
graft endothelialization was GE ¼ 10.0 6 6.3%; 18.7 6
11.3% and 40.0 6 35.1% at 2, 4, and 6 weeks, respectively.
ePTFE/PU composite grafts (straight). As early as
from week 4 onward, bilateral transanastomotic outgrowth
from both the aorta and the porous central PU segment led
to endothelial continuity in one-third of grafts making it
impossible to distinguish between transanastomotic and
transmural origin. From week 6 onward, all grafts showed
uninterrupted endothelial continuity (Figs 5 and 6, A).
The overall endothelial coverage of the entire graft was
GE ¼ 10.0 6 0.0; 37.2 6 17.0; 70.0 6 12.2 and 73.3 6
12.5% at 2, 4, 6, and 8 weeks.
ePTFE/PU composite grafts (looped). After 24
weeks, transanastomotic endothelialization reached
10.96 3.1 mm (Imax)/9.36 3.4mm (Imean) from the aorta
onto the proximal ePTFE segment of the loop and 14.1 6
7.1 mm (Imax)/10.9 6 5.3 mm (Imean) onto the distal one.
There was no signiﬁcant difference between proximal and
distal outgrowth. Over the entire observation period of
looped composite grafts, transanastomotic endothelial
outgrowth remained constant (Imax ¼ 0.7 6 0.9 mm/wk
/Imean ¼ 0.5 6 0.6 mm/wk at 6 weeks vs Imax ¼ 0.5 6
0.2 mm/wk / Imean ¼ 0.46 0.2 mm/wk at 24 weeks NS).
Endothelial outgrowth from the high-porosity central
PU segment onto the isolating ePTFE segments was ﬁrst
detectable at week 2. Until 24 weeks, it reached 5.4 6
6.7 mm (Imax)/3.8 6 4.2 mm (Imean) onto the proximal
ePTFE segment and 3.8 6 4.0 mm (Imax)/1.7 6
1.9 mm (Imean) onto the distal one (Fig 7).
At all time points, 100% of grafts maintained an endo-
thelial-free zone between the transanastomotic and the
transmural endothelium. Between week 6 and 24, the
endothelial-free zone decreased from 25.9 6 5.9 to
8.7 6 4.9 mm proximally and 21.9 6 13.4 to 12.3 6
6.2 mm distally (Fig 6, B).Midgraft endothelialization
ePTFE j ePTFE composite control grafts (straight).
Prior to the advancing transanastomotic endothelium
Fig 7. Stitched composite picture of the standard error of the
mean images used to analyze surface endothelialization. The
endothelialized areas were marked in red. The insert shows how
the transmural midgraft endothelium eventually also begins to
grow across the anastomotic seam line with the expanded poly-
tetraﬂuoroethylene (ePTFE) graft additionally narrowing the
endothelial-free zone from the midgraft side.
Fig 6. Endothelium-free zones on the low-porosity expanded
polytetraﬂuoroethylene (ePTFE) isolation segments. A, It is
obvious that, in contrast to straight composite grafts, the
endothelial-free zones in the loop grafts are sufﬁciently wide to
allow even longer implantation periods than 6 months. B, Between
week 6 and 24, there is no difference in the proximal and distal
endothelial-free zones.
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ePTFE control grafts (neither ePTFE-only nor ePTFE/
ePTFE composite grafts) showed any signs of midgraft
endothelium at any time point.
ePTFE/PU composite grafts (straight). Only one
(17%) of the 2-week composite grafts showed traces of
endothelium on the midgraft covering 7.3% (GSE 1.6 6
4.1%) of the PU surface as opposed to four (67%) of the
4-week explants that showed evidence of midgraft endo-
thelium (GSE ¼ 50.0 6 43.8%) (Fig 8). All of the 6- and
8-week samples had preconﬂuent to conﬂuent endothe-
lium on the high-porosity midgraft segment (GSE ¼
94.0 6 1348% and 90.0 6 14.1%, respectively).
ePTFE/PU composite grafts (looped). Except for
one 6-week graft and one 24-week graft, all loop graftsshowed the presence of endothelium on the PU segment
from week 6 onward. The nonendothelialized 24-week
graft had failed to embed in the retroperitoneum and as
such remained free-ﬂoating in the abdomen. In the absence
of any connection to surrounding tissue and a complete
lack of transmural capillaries, this graft was excluded from
the analysis. In the remaining 30/32 grafts, endothelial
coverage of the midgraft PU segment was 72.0 6 42.1%;
91.7 6 11.7%; 95.0 6 10.0% and 84.0 6 30.13% at 6, 8,
12, and 24 weeks, respectively (Fig 8).
Transmural vessel ingrowth. Apart from the one
excluded 24-week graft, all patent composite grafts
showed radial CD31-positive capillary ingrowth or endo-
thelial cells sprouting without a lumen into the PU segments
from the outside toward the blood surface. As early as at 2
weeks, transmural vessel ingrowth reached the inner third of
the graft wall in all implants while CD31-positive cells
remained scanty in the vicinity of the blood surface (Fig 9).
Intimal hyperplasia. The subintimal tissue on the
midgraft segment showed varying degrees of cellularity
and collagen content. Once a full endothelium was
established at 6 weeks, the subintimal thickness stayed
constant with a nonsigniﬁcant trend toward regression
(91.8 6 93.9 mm vs 71.4 6 59.4 mm at 6 and 24 weeks,
respectively; NS).
DISCUSSION
After decades of animal experiments that mostly failed
to distinguish between transanastomotic and transmural
Fig 9. Immunohistochemistry of the high-porosity polyurethane
(PU) midgraft segment of loop implants (12-week implants) and
scanning electron microscopy (SEM) of anastomosis. A, CD31-
positive endothelial cells cover the blood surface and are seen as
intramural vessels as well as single-stranded endothelial sprouts
(10). B, Neointima with conﬂuent endothelium on top of
a modest layer of alpha-actin-positive smooth muscle cells.
(Insert: 40) The large interconnecting pore sizes of $76 mm
enable arteriole ingrowth deep into the interstices of the graft wall
(40). C, SEM image depicting transanastomotic endothelializa-
tion of expanded polytetraﬂuoroethylene (ePTFE) isolation
segment (15)
Fig 8. Percentage of endothelial coverage of the high-porosity
midsection of composite grafts. The fact that the short, straight
composite grafts (gray) showed faster midgraft endothelialization
than the isolation loop grafts (black) highlights the likelihood of
transanastomotic outgrowth reaching the midgraft early in the
absence of sufﬁciently long “separation” distances.
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events in an infrarenal isolation model in the rat. By
implanting composite prostheses consisting of a high-
porosity midsegment welded into a low-porosity ePTFE
graft, we could demonstrate the following:
d In straight composite grafts, isolation segments were
too short making it impossible to distinguish between
transanastomotic and transmural endothelium.
d By extending the low-porosity isolation segments
through looping, broad endothelial-free zones were
maintained on either side of the midgraft in 100% of
implants even after half a year of implantation.
d From 6 weeks, transmural midgraft endothelium was
present in 93% of loop implants.
d Except for the initial 2 weeks, transanastomotic endo-
thelialization onto low-porosity ePTFE occurred at
a constant average speed of 0.3 to 0.4 mm/wk and
a maximal speed of 0.3 to 0.5 mm/wk.
d Subintimal tissue formation on midgrafts was modest
and did not progress once endothelial conﬂuence was
reached.
Given the continual presence of broad endothelial-free
separation zones in all loop grafts after half a year of
implantation, our rat model has allowed us, for the ﬁrst
time, to precisely assess modes of endothelialization other
than transanastomotic.
Notwithstanding, as the rat has always been a preferred
small animal screening model, it was extensively used in
vascular graft research in the past in spite of limited length
of suitable arteries. As a consequence, far too short grafts of
10- to 15-mm length were implanted.19-25 If one conserva-
tively extrapolates the transanastomotic outgrowth rates in
rats,22,25,26 it is highly likely that these experimental graftswere all transanastomotically fully endothelialized within
less than 10 weeks. Given the individual variability of trans-
anastomotic outgrowth, transanastomotic conﬂuence
needs to be assumed even earlier. In recognition of this
shortcoming, some researchers have emphasized the need
for additional graft length. As early as in 1984, Hess
et al27 suggested a looped conduit that enables the implan-
tation of graft lengths of up to 10 cm in the infrarenal aorta
of the rat. However, while loop grafts allowed longer
observation periods of transanastomotic outgrowth in
low-porosity ePTFE grafts,28 in high-porosity grafts
the line between transanastomotic and transmural
JOURNAL OF VASCULAR SURGERY
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prostheses permit transmural ingrowth across the entire
length of the grafts, transmural vessels could theoretically
contribute to the surface endothelium anywhere on the
graft including the proximity of the anastomoses.
Conversely, transanastomotic outgrowth has been
described to occur signiﬁcantly faster on high-porosity
grafts22,25 increasing the likelihood of endothelium to be
transanastomotic in origin even at considerable distance
from the anastomoses.
Therefore, as the transition zone where the two modes
of endothelialization coexist remained poorly deﬁned,
extending the graft length by looping did not result in
a model that allowed the assessment of transmural events
without transanastomotic interference. In view of the insig-
niﬁcance of transanastomotic endothelialization in clinically
implanted grafts, a model was therefore needed that guaran-
tees clearly discernible endothelial-free zones on either side
of a high-porosity graft. By “welding” a short high-porosity
segment into the center of a low-porosity graft, a separation
of events was achieved. However, as the transmurally
formed midgraft endothelium eventually began to also
grow onto the low-porosity isolation segments, the
endothelium-free separation zone disappeared rapidly in
straight infrarenal interposition grafts because of their
anatomic length limitation. By week 4, the two outgrowth
margins had coalesced in 50% of implants and from week
6 onward, none of the straight composite grafts allowed
the distinction between midgraft and transanastomotic
endothelium any longer. Carrying the isolation principle
over into loop grafts substantially increased the length
of the isolation segments thereby guaranteeing a distinct
endothelial-free separation zone that allowed the observa-
tion of transmural endothelialization without transanasto-
motic interference for up to half a year. Extrapolating the
relatively constant mid- to long-term transanastomotic
outgrowth rate of the present study of 0.2 to 0.3 mm/
wk, it is likely that the isolation loop model will maintain
a discernible endothelium-free isolation zone for up to
a year. The fact that the outgrowth rate corresponds with
previous observations25,30 conﬁrms the reproducibility of
the model.
Isolated from transanastomotic endothelialization by
endothelial-free zones, the high-porosity midgrafts experi-
enced abundant vessel ingrowth from the surrounding
tissue in 31 of 32 rats. In 50% of implanted loop grafts,
transmural blood vessels reached the blood surface as early
as after 2 weeks, comparable to juvenile baboons31 but
earlier than in dogs32 or senescent baboons.1 Only one
graft failed to embed in the retroperitoneal tissue and
remained freely ﬂoating in the abdomen. On gross exami-
nation, the porous midsegment was covered by a white
smooth capsule. On histology, smooth muscle cells, macro-
phages, and collagen were present in the pores of the graft
in the absence of even traces of an endothelium. Although
this observation supports Julie Campbell’s33 ﬁnding that
peritoneal macrophages are capable of transdifferentiating
into ﬁbroblasts and vascular smooth muscle cells, it putsthe signiﬁcance of “fallout” healing into perspective.
Although described by Lester Sauvage’s group34 and Shi
et al35 as a possible source of midgraft endothelialization,
the absolute lack of any traces of endothelium in the absence
of transmural capillary ingrowth in the present study
suggests that in this model, the main source of midgraft
endothelium is transmural capillary ingrowth rather than
bloodborne endothelial or progenitor cells. However, to
ﬁrmly exclude the possibility of “fallout” healing, isolation
loop-graft experiments will be required where the central
high-porosity segment is sealed inside a low-porosity wrap
of a pore size small enough to prevent capillary ingrowth
but sufﬁciently porous to avoid the dismal occlusion rates
of nonporous small-diameter grafts. Alternatively, distal
arteriovenous ﬁstulae have led to at least some degree of
patency in impervious grafts that were sealed with silicone
on their outside.34 The presence of small endothelial islands
after 3months of implantation in dogs conﬁrmed34 the prin-
cipal possibility of blood-derived fallout healing, while
excluding it as a predominant mode of endothelialization.
Similarly, small traces of endothelial islands were occasion-
ally detectable on low-porosity woven Dacron prostheses
in humans after prolonged implantation periods.36 Overall,
however, the observation of fallout healing has been scanty
and so far limited to Dacron surfaces.34-36
In summary, we established a small animal vascular
model that allowed us to study transmural endothelializa-
tion in isolation without the distorting presence of a pre-
existing transanastomotic endothelium. This also allowed
us to address two concerns potentially jeopardizing its ulti-
mate clinical success. One of these concerns is the fear that
concomitant neointimal tissue proliferation may not be
self-limiting. Although previous experiments have consis-
tently shown a rapid appeasement of subintimal mitotic
activity over time both in the rat22,37 and in the baboon
model,38,39 one could argue that accelerated endothelial
conﬂuence because of transanastomotic contribution may
have mitigated the process. The modest neointimal
response we saw in the present study and its trend toward
regression over time, however, conﬁrmed the self-limiting
nature of neointimal proliferation in isolated midgrafts.
The other concern relates to the suspected adverse
build-up of increasingly hostile and impenetrable ﬁbrin in
the innermost graft layer1,40 before transmural vessel
ingrowth can reach the blood surface. The goal will be to
accelerate capillary ingrowth41 or to prevent the gradual
compaction of ﬁbrin. For both, a small animal model will
be needed that allows the investigation of these processes
over extended periods of time without the interference of
transanastomotic endothelium.AUTHOR CONTRIBUTIONS
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